

Maurice P H M Jansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7783518/publications.pdf>

Version: 2024-02-01

38
papers

2,083
citations

304743

22
h-index

361022

35
g-index

40
all docs

40
docs citations

40
times ranked

3747
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. BMC Cancer, 2022, 22, 165.	2.6	8
2	Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling. Clinical Chemistry, 2022, 68, 963-972.	3.2	10
3	The COMPLETE trial: Holistic early response assessment for oropharyngeal cancer patients; Protocol for an observational study. BMJ Open, 2022, 12, e059345.	1.9	0
4	Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. Molecular Oncology, 2021, 15, 57-66.	4.6	28
5	Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. BMC Cancer, 2021, 21, 315.	2.6	18
6	Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients. Genome Medicine, 2021, 13, 86.	8.2	14
7	Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis. Annals of Translational Medicine, 2021, 9, 1264-1264.	1.7	12
8	High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2 ⁺ postmenopausal breast cancer patients treated with everolimus and exemestane. Molecular Oncology, 2020, 14, 490-503.	4.6	14
9	TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer. Biomolecules, 2020, 10, 415.	4.0	23
10	RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-confirmed RAS wild-type advanced colorectal cancer. Molecular Oncology, 2019, 13, 2361-2374.	4.6	32
11	High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. Molecular Oncology, 2019, 13, 392-402.	4.6	37
12	An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. Journal of Molecular Diagnostics, 2019, 21, 123-137.	2.8	15
13	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. Molecular Oncology, 2018, 12, 48-57.	4.6	52
14	Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions. Molecular Oncology, 2017, 11, 295-304.	4.6	123
15	Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA. Scientific Reports, 2017, 7, 2136.	3.3	7
16	Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis. Translational Oncology, 2017, 10, 854-866.	3.7	5
17	Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. Oncotarget, 2016, 7, 43412-43418.	1.8	30
18	LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome. Molecular Oncology, 2016, 10, 1363-1373.	4.6	23

#	ARTICLE	IF	CITATIONS
19	Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. <i>Molecular Oncology</i> , 2016, 10, 1575-1584.	4.6	61
20	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	2.6	25
21	SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. <i>American Journal of Cancer Research</i> , 2016, 6, 270-84.	1.4	5
22	Decreased expression of ABAT and STC2 hallmarks ER α -positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015, 9, 1218-1233.	4.6	64
23	Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. <i>BMC Cancer</i> , 2015, 15, 588.	2.6	24
24	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 39-49.	2.5	49
25	Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6632-6641.	0.9	79
26	mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11045-11045.	1.6	0
27	Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture. <i>Gynecologic Oncology</i> , 2010, 117, 170-176.	1.4	76
28	Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGF β and regulating microRNAs. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 25-30.	2.8	49
29	Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 263-271.	2.5	35
30	Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 275-283.	2.5	56
31	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. <i>BMC Genomics</i> , 2008, 9, 239.	2.8	300
32	Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response. <i>Clinical Cancer Research</i> , 2008, 14, 5555-5564.	7.0	155
33	HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 662-668.	1.6	118
34	Molecular profiling of platinum resistant ovarian cancer. <i>International Journal of Cancer</i> , 2006, 118, 1963-1971.	5.1	139
35	In reply to the letter by Gevaert et al.. <i>International Journal of Cancer</i> , 2006, 119, 1512-1512.	5.1	0
36	Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1851-1852.	6.3	10

#	ARTICLE	IF	CITATIONS
37	Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. Journal of Clinical Oncology, 2005, 23, 732-740.	1.6	322
38	Three Hsp70 Genes Are Located in the C4-H-2D Region: Possible Candidates for the Orch-1 Locus. Genomics, 1993, 15, 350-356.	2.9	65